| (1) |
Nordyke RA, Gilbert Jr FI. Management of primary hypothyroidism. Compr
Ther 1990; 16: 28-32. |
| (2) |
Ain KB, Refetoff S, Fein HG, Weintraub BD. Pseudomalabsorption
of levothyroxine. JAMA 1991; 266: 2118-2220. |
| (3) |
Sarlis NJ, Brucker-Davis F, Doppman JL, Skarulis MC. MRI-demonstrable
regression of pituitary mass in a case of primary hypothyroidism after a
week of acute thyroid hormone therapy. J Clin Endocrinol Metab 1997;
82: 808-811. |
| (4) |
Wood LC. Support groups for patients with Graves' disease and other thyroid
conditions. End Metab Clin North Am 1998; 27: 101-107. |
| (5) |
Schectman JM, Elinsky EG, Pawlson LG. Effect of education and feedback
on thyroid function testing strategies of primary care clinicians. Arch
Intern Med 1991; 151: 2163-2166. |
| (6) |
Davies PDO, Lazarus JH, Wheeler MH. A computer-assisted thyroid follow-up
system. World J Surg 1986; 10: 681-686. |
| (7) |
Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription
in the community: serum thyroid stimulating hormone level assays as an indicator
of undertreatment or overtreatment. Br J Gen Pract 1993; 43: 107-109. |
| (8) |
Tan SY, Gill GV, Hales T. Thyroid register audit: a district general hospital
experience. Postgrad Med J 1992; 68: 483-484. |
| (9) |
Ain KB, Pucino F, Csako G, Wesley RA, Drass JA, Clark C, et al. Effects
of restricting levothyroxine dosage strength availability. Pharmacotherapy
1996; 16: 1103-1110. |
| (10) |
Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole
compared to every 8hours propylthiouracil in the treatment of hyperthyroidism.
South Med J 1995; 88: 973-976. |
| (11) |
Hermus Ad R, Huysmans DA. Treatment of benign nodular thyroid disease.
N Engl J Med 1998; 338: 1438-1447. |
| (12) |
Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison
of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic
non-toxic goitre. Lancet 1990; 336: 193-197. |
| (13) |
Weetman AP. Hypothyroidism: screening and subclinical disease. BMJ
1997; 314: 1175-1178. |
| (14) |
Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of
chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum.
J Clin Endocrinol Metab 1992; 75: 1333-1338. |
| (15) |
Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol
Metab Clin North Am 1998; 27: 37-49. |
| (16) |
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al.
Low serum thyrotropin: a risk factor for atrial fibrillation in older persons.
N Engl J Med 1994; 331: 1249. |
| (17) |
Leese GP, Jung RT, Gutherie C, Waugh N, Browing MC. Morbidity in patients
on L-thyroxine: a comparison of those with a normal TSH to those with a
suppressed TSH. Clin Endocrinol (Oxf) 1992; 37: 500. |
| (18) |
Franklyn JA, Daykin J, Betteridge J, Hughes EA, Holder R, Jones SR, et
al. Thyroxine replacement therapy and circulating lipid concentrations.
Clin Endocrinol (Oxf) 1993; 38: 453. |
| (19) |
Faber J, Galloe M. Changes in bone mass during prolonged subclinical hyperthyroidism
due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;
130: 350-356. |
| (20) |
Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects
on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab 1996; 81: 4278-4289. |
| (21) |
Vrobel TR, Miller PF, Mostow ND, Rakita L. A general overview of amiodarone
toxicity: its prevention, detection and management. Prog Cardiovasc Dis
1989; 31: 393-426. |
| (22) |
Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann
Intern Med 1997; 126: 63-73. |
| (23) |
Wiersinga WM. Amiodarone and the thyroid. In: Weetman AP, Grossman A,
eds. Pharmacotherapeutics of the thyroid gland. Berlin: Springer-Verlag,
1997:225-287. |
| (24) |
Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts
by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy.
Clin Endocrinol 1994; 40: 67-72. |
| (25) |
Prummel MF, van Pareren Y, Bakker O, Wiersinga WM. Anti-heat shock protein
(hsp)72 antibodies are present in the patients with Graves' disease (GD)
and in smoking control subjects. Clin Exp Immunol 1997; 110: 292-295. |
| (26) |
Hofbauer LC, Muhlberg T, Konig A, Heufelder G, Schworm HD, Heufelder AE.
Soluble interleukin-1 receptor antagonist serum levels in smokers and non
smokers with Graves' ophthalmopathy undergoing orbital radiotherapy. J
Clin Endocrinol Metab 1997; 82: 2244-2257. |
| (27) |
DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marocci C, Weirsinga WM,
et al. Therapeutic controversies: radiation and Graves' ophthalmopathy.
J Clin Endocrinol Metab 1995; 80: 339-349. |
| (28) |
Bartalena L, Marocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et
al. Relationship between therapy for hyperthyroidism and the course of Graves'
ophthalmopathy. N Engl J Med 1998; 338: 73-78. |
| (29) |
Tallestedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H,
et al. Occurrence of ophthalmopathy after treatment of Graves' hyperthyroidism.
N Engl J Med 1992; 326: 1733-1738. |
| (30) |
Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998;
338: 121-122. |
| (31) |
International agranulocytosis and aplastic anaemia study. Risk of agranulocytosis
and aplastic anaemia in relation to the use of antithyroid drugs. BMJ
1988; 297: 262-265. |
| (32) |
Anon. Drug-induced agranulocytosis. Drug Ther Bull 1997; 35: 49-52. |
| (33) |
Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced
agranulocytosis. The usefulness of routine white blood cell count monitoring.
Arch Intern Med 1990; 150: 621-624. |
| (34) |
Anon. Reminder: agranulocytosis with antithyroid drugs. Curr Probl
Pharmacovigilance 1999; 25: 3. |